Ascendis Pharma AS
(BSP:A1SN34)
R$
48.84
0 (0%)
Market Cap: 2.92 Bil
Enterprise Value: 5.48 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 64/100 
Ascendis Pharma A/S at Leerink Global Healthcare Conference Transcript
Feb 25, 2020 / 04:30PM GMT
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst
Good morning, everyone. Joe Schwartz, covering analyst for Ascendis. Very pleased to be joined by Jan Mikkelsen and Scott Smith, to give us an update at a very exciting time.
Questions & Answers
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst
Good morning, gentlemen. Maybe we can just ask you to give us a quick lay of the land before we dive into some more specifics around each of your programs.
Jan MÃ;ller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director
¸ - /- -
First of all, thanks, Joe, for inviting us. It's always a pleasure to be here.
Yes. Ascendis Pharma, we have been executing the last years about our Vision 3x3, which is our strategic pathway how to be a leading biopharma company, and it's basic building a
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers